…
Adherium Limited, a digital health company, develops, manufactures, and supplies digital health technologies that address sub-optimal medication use and improve health outcomes in chronic diseases. The company offers Hailie Smartinhaler, a cloud-based platform which captures medication use data from Bluetooth enabled sensors which wrap around patient inhalers and provide real-time feedback to patients; Hailie Smartinhaler Sensors, a device coverage that works for Rescuer/Reliever and Preventer inhalers; Hailie solution; and Hailie Remote Patient Monitoring (RPM) Solution. It operates in New Zealand, Australia, South East Asian Countries, and North America. Adherium Limited was founded in 2001 and is based in Melbourne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Adherium Ltd develops digital inhaler sensors and a cloud-based adherence platform for asthma and COPD to record inhaler use and enable remote monitoring. Long-term growth may be supported by rising adoption of digital health, recurring device and data services, and partnerships with healthcare organisations and pharmaceutical companies, making it relevant to investors interested in respiratory digital tools.
Key risks include limited scale and revenue, execution and commercialisation challenges, competitive pressure, regulatory and reimbursement uncertainty, and potential need for additional capital.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -15.26M | -12.68M | -10.22M | -9.86M | -11.22M |
| Net income | -14.16M | -12.68M | -10.22M | -9.86M | -11.22M |
| Selling general administrative | - | 5.49M | 5.06M | 4.85M | 5.36M |
| Selling and marketing expenses | - | 4.29M | 2.14M | 4.01M | 0.94M |
| Gross profit | 1.22M | 0.11M | 0.27M | 2.52M | 0.32M |
| Reconciled depreciation | - | - | 0.11M | 0.19M | 0.18M |
| Ebit | - | -12.54M | -11.67M | -9.85M | -11.22M |
| Ebitda | -14.36M | -12.44M | -11.56M | -9.66M | -11.04M |
| Depreciation and amortization | - | 0.10M | 0.11M | 0.19M | 0.18M |
| Operating income | -14.36M | -12.54M | -12.09M | -9.85M | -11.22M |
| Other operating expenses | 16.46M | 13.36M | 12.93M | 15.28M | 13.59M |
| Interest expense | 0.96M | 0.23M | 0.00M | 0.01M | 0.00M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.14M | 0.24M | 0.20M | 0.02M |
| Net interest income | - | - | 0.24M | 0.20M | 0.02M |
| Income tax expense | -1.09M | - | -1.45M | 1.84M | 0.00M |
| Total revenue | 2.10M | 0.82M | 0.84M | 3.19M | 0.53M |
| Total operating expenses | 15.58M | 12.65M | 12.36M | 14.61M | 13.38M |
| Cost of revenue | 0.88M | 0.71M | 0.57M | 0.67M | 0.21M |
| Total other income expense net | -0.90M | -0.14M | 1.87M | 1.84M | -0.00M |
| Net income from continuing ops | - | - | -10.22M | -9.86M | -11.22M |
| Net income applicable to common shares | - | -12.68M | -10.22M | -9.86M | -11.22M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 4.56M | 3.52M | 9.89M | 12.68M | 7.36M |
| Intangible assets | - | 0.00M | - | 0.04M | 0.00M |
| Other current assets | 0.11M | 1.44M | 0.15M | 0.23M | 0.27M |
| Total liab | 5.85M | 8.28M | 3.41M | 3.47M | 3.00M |
| Total stockholder equity | -1.29M | -4.76M | 6.48M | 9.21M | 4.36M |
| Other current liab | 0.30M | 2.04M | - | 1.81M | 1.21M |
| Common stock | 149.66M | 132.13M | 131.00M | 123.62M | 110.52M |
| Capital stock | - | - | - | 123.62M | 110.52M |
| Retained earnings | -130.35M | -116.19M | 103.51M | -93.29M | -84.61M |
| Other assets | - | - | 0.00M | - | - |
| Cash | 1.42M | 0.04M | 6.20M | 9.08M | 5.28M |
| Cash and equivalents | - | - | - | 9.08M | 5.28M |
| Total current liabilities | 5.83M | 8.25M | 3.36M | 3.47M | 2.95M |
| Current deferred revenue | 0.49M | - | 0.57M | 0.66M | 1.21M |
| Net debt | 0.98M | 3.08M | -6.10M | -9.03M | -5.20M |
| Short term debt | 2.40M | 3.12M | 0.05M | 0.04M | 0.04M |
| Short long term debt total | 2.40M | 3.12M | 0.09M | 0.04M | 0.09M |
| Other stockholder equity | - | - | -249.05M | -21.12M | -21.55M |
| Property plant equipment | - | - | - | 0.13M | 0.31M |
| Total current assets | 4.50M | 3.40M | 9.73M | 12.51M | 7.05M |
| Net tangible assets | - | - | - | 9.21M | 4.36M |
| Net receivables | 1.74M | 0.08M | 1.80M | 1.97M | 0.42M |
| Inventory | 1.23M | 1.84M | 1.58M | 1.24M | 1.07M |
| Accounts payable | 2.63M | 3.09M | 2.75M | 0.96M | 1.70M |
| Accumulated other comprehensive income | -20.59M | -20.71M | 21.01M | -21.12M | -21.55M |
| Non currrent assets other | - | - | 0.00M | - | - |
| Non current assets total | 0.07M | 0.12M | 0.16M | 0.17M | 0.31M |
| Capital lease obligations | - | - | - | 0.04M | 0.09M |
| Long term debt total | - | - | - | 0.00M | 0.04M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | - | -0.00M | -0.04M | -0.28M |
| Change to liabilities | - | - | - | 0.34M | 0.05M |
| Total cashflows from investing activities | -0.04M | -0.05M | -0.00M | -0.04M | -0.28M |
| Total cash from financing activities | 16.32M | 3.87M | 7.73M | 13.07M | 1.43M |
| Net income | -14.16M | -12.68M | -10.22M | -9.86M | -10.04M |
| Change in cash | 1.38M | -6.15M | -2.88M | 3.79M | -9.89M |
| Begin period cash flow | 0.04M | 6.20M | 9.08M | 5.28M | 15.18M |
| End period cash flow | 1.42M | 0.04M | 6.20M | 9.08M | 5.28M |
| Total cash from operating activities | -14.83M | -9.98M | -10.61M | -9.28M | -9.61M |
| Issuance of capital stock | - | - | 8.37M | 13.81M | - |
| Depreciation | - | 0.10M | 0.11M | 0.19M | 0.19M |
| Other cashflows from investing activities | - | - | 0.00M | - | - |
| Change to inventory | - | -0.23M | -0.35M | -0.15M | -0.14M |
| Change to account receivables | - | 0.18M | -0.09M | -0.30M | -1.19M |
| Sale purchase of stock | - | - | -0.64M | -0.74M | 0.00M |
| Other cashflows from financing activities | - | - | -0.00M | -0.04M | -0.28M |
| Change to netincome | - | - | - | 0.50M | 1.53M |
| Capital expenditures | 0.04M | 0.05M | 0.00M | 0.04M | 0.28M |
| Change in working capital | - | 2.46M | -0.82M | -0.11M | -1.28M |
| Stock based compensation | - | 16.32M | - | 0.52M | 1.50M |
| Other non cash items | -0.67M | -16.19M | 0.43M | 0.42M | 3.76M |
| Free cash flow | -14.87M | -10.03M | -10.61M | -9.32M | -9.89M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ADR Adherium Ltd |
- -% |
0.05 | - | 0.91 | 1.25 | 2.84 | 1.72 | -0.20 |
| COH Cochlear Ltd |
-3.88 2.52% |
149.99 | 68.39 | 29.76 | 4.29 | 5.75 | 4.28 | 30.27 |
| IMR Imricor Medical Systems Inc |
0.01 1.15% |
1.32 | - | - | 16567.91 | 17.45 | 4019.33 | -2.60 |
| AVH Avita Medical Inc |
-0.40 7.84% |
4.70 | - | 9.97 | 9.54 | 7.17 | 6.33 | 15.37 |
| AVR Anteris Technologies Global Corp |
-0.33 4.19% |
7.55 | - | - | 329.44 | 2.32 | 145.60 | -5.20 |
Adherium Limited, a digital health company, develops, manufactures, and supplies digital health technologies that address sub-optimal medication use and improve health outcomes in chronic diseases. The company offers Hailie Smartinhaler, a cloud-based platform which captures medication use data from Bluetooth enabled sensors which wrap around patient inhalers and provide real-time feedback to patients; Hailie Smartinhaler Sensors, a device coverage that works for Rescuer/Reliever and Preventer inhalers; Hailie solution; and Hailie Remote Patient Monitoring (RPM) Solution. It operates in New Zealand, Australia, South East Asian Countries, and North America. Adherium Limited was founded in 2001 and is based in Melbourne, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Rick Legleiter B.S., M.B.A. | Chief Exec. Officer | 1959 |
| Mr. Geoff Feakes | Chief Technology Officer | NA |
| Mr. Rob Turnbull B.Com., C.A., B.Com, CA. | GM & Joint Company Sec. | 1967 |
| Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSP | Joint Company Sec. | 1964 |
| Mr. Daniel Kaplon | Chief Financial Officer | NA |
| Ms. Kirsty Rutledge-Malyon | HR Mang. | NA |
| Ms. Maggie Scott | Head of Clinical Operations | NA |
| Mr. Michael Motion | Consultant | NA |
| Dr. John Douglas Wilson | Exec. Medical Director | 1937 |
| Mr. Louis James Panaccio BEC, C.A., M.A.I.C.D. | Executive Chairman of the Board | 1957 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.